Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study
Germline BRCA1/2 mutations are associated with higher pCR rates and improved DMFS in breast cancer patients treated with NCT. These findings emphasize the enhanced chemosensitivity of BRCA-associated tumors and the importance of genetic testing in treatment planning. Further research is needed to validate these findings and optimize treatment strategies.
Authors
- Wonshik Han (ORCID: https://orcid.org/0000-0001-7310-0764)
- Jinseob Kim (ORCID: https://orcid.org/0000-0002-9403-605X)
- Hyeong‐Gon Moon (ORCID: https://orcid.org/0000-0002-9981-0286)
- Eun-Shin Lee (ORCID: https://orcid.org/0000-0003-0778-9713)
- Seung Pil Jung (ORCID: https://orcid.org/0000-0003-3967-2974)
- Seung Gyu Yun (ORCID: https://orcid.org/0000-0002-9915-9681)
- Jung Whan Chun (ORCID: https://orcid.org/0000-0001-6438-5526)
- Hyunyou Kim (ORCID: https://orcid.org/0000-0002-1656-2337)
- Jinha Hwang (ORCID: https://orcid.org/0000-0003-0780-1129)
Institutions
- Seoul National University (KR)
- Korea University Medical Center (KR)
- Korea Pharma (South Korea) (KR)
- Korea University (JP)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s13058-025-02041-6
- Citations
- 1
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- National Research Foundation
- Korea University
- National Research Foundation of Korea
- Ministry of SMEs and Startups
- Korea University Anam Hospital